- Robert McIntyre (co-founder of Nectome) was invited to the channel; he previously discussed aldehyde-stabilized cryopreservation (ASC) using glutaraldehyde to cross-link brain tissue for long-term structural preservation.  
- Debate over ASC’s feasibility: critics argue glutaraldehyde irreversibly destroys cellular proteins, while supporters cite electron-microscopy evidence showing ultrastructure comparable to optimally cryo-fixed tissue and view it as a bridge to future repair technologies.  
- Cryonics economics discussed: traditional liquid-nitrogen storage (Alcor, CI) versus aldehyde fixation plus dry-ice or LN2; compound-interest endowments and long-term institutional funding models were contrasted with Ponzi-scheme fears and geopolitical risks.  
- Alternative preservation ideas floated: reversible enzymatic cross-linkers (e.g., DNA-encoded restriction sites), spiroligomer-based molecular tools, and Antarctic or Svalbard permafrost bunkers to reduce infrastructure dependence.  
- Regulatory and ethical controversies: assisted-suicide proposals for terminal patients, municipal bans on “keeping bodies,” and Wikipedia’s alleged anti-transhumanist editing wars highlighted cultural resistance to experimental brain preservation.  
- Comparative service models: Nectome’s refundable deposits for future ASC, KrioRus’s lower-cost LN2 storage via life-insurance trusts, and DIY dry-ice options were weighed for cost, reliability, and legal risk.  
- Ancillary topics: David Sinclair’s resveratrol/longevity work dismissed as “crookery,” over-the-counter availability of metformin and modafinil across jurisdictions, and the broader difficulty of funding biology research without overstated promises.